Rezolute Q3 FY2023 net loss $15.7M; cash $129.2M; Phase 3 for RZ358 on track for Q3 2023

Rezolute, Inc.

2023-Q3 EPS reported -$0.76

Net loss of $15.7M for Q3 FY2023, compared to $11.2M in same period last year.
Cash and equivalents $33.7M plus marketable debt securities $95.5M as of March 31, 2023.
R&D expenses rose to $14.2M from $8.7M, driven by clinical trial and manufacturing costs.
Company expects to commence Phase 3 study for RZ358 in Q3 calendar 2023; Phase 2 for RZ402 enrolling.
G&A expenses increased to $2.9M from $2.1M due to higher personnel and stock-based compensation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Rezolute, Inc. reported third quarter of fiscal 2023 ended March 31, 2023 results: net income $15.7 million.

Period: third quarter of fiscal 2023 ended March 31, 2023
Net income: $15.7 million
Result: reported results

Exact text from the filing

Net loss was $15.7 million for the third quarter of fiscal 2023, compared to $11.2 million for the same period in fiscal 2022.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Rezolute, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-059147

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.